Hosted on MSN10mon
DCGI orders withdrawal of Olaparib for select cancer patients over safety concernsNew Delhi: The Drug Controller General of India (DCGI), Rajeev Raghuvanshi, has directed state authorities to withdraw AstraZeneca’s Olaparib Tablets, 100mg and 150mg, due to potential adverse ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of ...
But he said olaparib offers a treatment option “demonstrating a significant delay in cancer progression or death compared to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback